Filing Season Finds: Valeant Pharmaceuticals (VRX)
Analyst Cody Fincher made a total of 44 adjustments to Valeant’s financial statements with a total value of $50 billion. Here are our four largest takeaways from Valeant’s 10-K.
Sam McBride